Upcoming Conferences

Foresight from the COVID-19 Pandemic (FCP)
06-01-2022 - 12-31-2022

Introduction COVID-19 has taught the world, once again, the painful lesson that the lack of preparedness for infectious disease pandemics is a tragic ...    


Agricultural Biosurveillance, Biosecurity, and Biodefense (ABBB)
06-01-2022 - 12-31-2022

Introduction: The vulnerabilities of the U.S. food and agricultural systems to natural and intentional attack and alteration have long been recognize...    


GPHEF - Production and Exportation
08-15-2022 - 08-19-2022

Introduction: The often-dramatic advancements in science and technology that have characterized the outset of the 21st century are now important tools...    


GPHEF - Importation and Innovation
09-26-2022 - 09-30-2022

Introduction: The often-dramatic advancements in science and technology that have characterized the outset of the 21st century are now important tools...    


Licensing Innovative Food Additives and Ingredients by FDA

The current system for ensuring the safety of innovative food additives and ingredients was developed by Congress in 1958. It is inadequate in today’s marketplace where supply chains are more complex, dynamic, and global, and our understanding of health risks has greatly advanced. The food supply is at risk for allowing unsafe substances to threaten serious long-term health effects as long as the Food and Drug Administration (FDA) allows companies to self-certify that a substance’s use is Generally Recognized As Safe (GRAS*) without the agency’s or the public’s knowledge. Rather than embracing innovation, consumers increasingly recognize the risk, and most see substances added to food as their most important food-safety issue. Congress needs to modernize the mechanisms that ensure safety in a way that supports innovators who develop safe substances through a process that consumers can trust. To be successful, the dynamic needs to change from a race to the bottom with respect to safety research to one which strongly incentivizes companies to invest in robust safety studies by protecting them from “copycat” competitors who rely on the innovator’s research and granting a longer license from FDA when the evidence is compelling.